Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Equity Average (2016 - 2025)

Enanta Pharmaceuticals filings provide 13 years of Equity Average readings, the most recent being $95.7 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 20.5% to $95.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $95.7 million, a 20.5% decrease, with the full-year FY2025 number at $96.8 million, down 43.99% from a year prior.
  • Equity Average hit $95.7 million in Q4 2025 for Enanta Pharmaceuticals, up from $72.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $444.0 million in Q1 2021 to a low of $72.0 million in Q3 2025.
  • Median Equity Average over the past 5 years was $240.4 million (2023), compared with a mean of $247.7 million.
  • Biggest five-year swings in Equity Average: dropped 8.29% in 2021 and later crashed 48.15% in 2025.
  • Enanta Pharmaceuticals' Equity Average stood at $391.9 million in 2021, then dropped by 20.62% to $311.1 million in 2022, then plummeted by 34.32% to $204.3 million in 2023, then crashed by 41.11% to $120.3 million in 2024, then decreased by 20.5% to $95.7 million in 2025.
  • The last three reported values for Equity Average were $95.7 million (Q4 2025), $72.0 million (Q3 2025), and $86.4 million (Q2 2025) per Business Quant data.